Scleroderma Foundation Representatives Attend
American College of Rheumatology Annual Meeting
Members of the Scleroderma Foundation's national office were
in San Francisco, Calif., last week for the annual meeting of the American
College of Rheumatology (ACR). More than 16,000 rheumatologists, clinical researchers and other professionals from around the
world were at the meeting. The Foundation experienced a large number of
visitors to its booth. During the event, the Foundation announced its upcoming Continuing Medical Education program for physicians and nurses. The new course with be on Difficult Management
Problems in Systemic Sclerosis for physicians and nurses.
ACR is an important venue for the Foundation to strengthen
relationships with physicians, current and potential funding partners,
patient/membership organizations and others. An in-depth article on current
research results, findings, and advances reported at the meeting, be sure to
tune in to our Spring edition of the “Scleroderma Voice”. If you would like to
receive this quarterly magazine, we welcome you to become a member of the Foundation.
Video: Medical Emergency Readiness
Dr. Murtaza Cassoobhoy provides tips to help you successfully navigate the hospital system from an initial emergency room visit through an inpatient stay. The "Medical Emergency Readiness" workshop was presented at the 2015 National Patient Education Conference in Nashville.
Scleroderma Foundation Announces New Board Members
The Scleroderma Foundation recently elected three new members to serve on the
Foundation's National Board of Directors. The Foundation is excited to welcome Katayun (Kathy) Jaffari, Bill Martin and Bruce Cowan to the board.
New Study Reveals Promising Treatment for Interstitial Lung Disease
Lung complications of scleroderma are potentially very serious. One complication is interstitial lung disease, which is characterized by progressive scaring of the lung tissue that eventually hinders a person's ability to breathe. A new two-year study shows mycophenolate motifil to be as effective cyclophosphamide in treating interstitial lung disease.
Disclaimer: The Scleroderma Foundation in no way
endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is
provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.
The Scleroderma Foundation is a qualified national nonprofit operating under 501(c)(3) status. The foundation’s federal tax identification number is 52-1375827. Our primary goal is to raise funds for our three-fold mission of support, education and research. The foundation has 20 active chapters and 160 support groups across the country.